MEDINCELL S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.9 EUR | -4.05% |
|
+17.84% | +51.39% |
| Apr. 17 | Medincell: share price rises following agreement with AbbVie | CF |
| Apr. 16 | Medincell, AbbVie to Co-Develop Injectable Therapeutics | DJ |
| Sales 2024 * | 13.96M 14.86M | Sales 2025 * | 40.75M 43.37M | Capitalization | 313M 334M |
|---|---|---|---|---|---|
| Net income 2024 * | -23M -24.48M | Net income 2025 * | 1M 1.06M | EV / Sales 2024 * | 25.9 x |
| Net Debt 2024 * | 48.73M 51.87M | Net Debt 2025 * | 58.83M 62.62M | EV / Sales 2025 * | 9.13 x |
| P/E ratio 2024 * |
-12.4
x | P/E ratio 2025 * |
-189
x | Employees | 138 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 49.98% |
More Fundamentals
* Assessed data
More news
Latest transcript on MedinCell S.A.
More press releases
More news
| 1 day | -4.05% | ||
| 1 week | +17.58% | ||
| Current month | +13.66% | ||
| 1 month | +17.46% | ||
| 3 months | +35.57% | ||
| 6 months | +70.31% | ||
| Current year | +51.39% |
1 week
9.05
11.68
1 month
9.0511.68
Current year
6.9111.68
1 year
5.2511.68
3 years
4.7311.68
5 years
4.3520.00
10 years
4.3520.00
| Managers | Title | Age | Since |
|---|---|---|---|
Christophe Douat
CEO | Chief Executive Officer | 60 | 03-01-08 |
Stéphane Postic
DFI | Director of Finance/CFO | 50 | 23-08-31 |
| Chief Tech/Sci/R&D Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sabri Markabi
BRD | Director/Board Member | - | 17-07-04 |
Tone Kvåle
BRD | Director/Board Member | 55 | 22-06-12 |
Virginie Lleu
BRD | Director/Board Member | - | 16-05-24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 10.9 | -4.05% | 229,245 |
| 24-04-17 | 11.36 | +22.02% | 977,484 |
| 24-04-16 | 9.31 | +1.20% | 62,672 |
| 24-04-15 | 9.2 | +0.33% | 28,747 |
| 24-04-12 | 9.17 | -0.86% | 26,376 |
Real-time Euronext Paris, April 18, 2024 at 11:35 am EDT
More quotes
MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable.
As of March 31, 2023, the company had a portfolio of 2 products in phase 3 clinical development and 6 products in preclinical development. Its most advanced product, mdc-IRM/UZEDYTM for the treatment of schizophrenia, has received marketing authorization in the United States.
Sector
Pharmaceuticals
Calendar
2024-06-25
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
10.9
EUR
Average target price
16.75
EUR
Spread / Average Target
+53.67%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +51.39% | 347M | |
| +27.97% | 676B | |
| +23.58% | 554B | |
| -7.02% | 349B | |
| +14.85% | 318B | |
| +6.25% | 291B | |
| +2.96% | 210B | |
| -0.41% | 204B | |
| -10.02% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- MEDCL Stock
